COO (The Cooper) 1-Year Sharpe Ratio: 0.03 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COO The Cooper Companies Inc COO
89 GF Score
Price $73.10
GF Value $101.24
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is The Cooper 1-Year Sharpe Ratio?

The Cooper COO +3.54% 89 1-Year Sharpe Ratio is 0.03 as of Jul. 17, 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $101.24 (Modestly Undervalued). The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-17), The Cooper's 1-Year Sharpe Ratio is 0.03.

The Cooper  (NAS:COO) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

The Cooper 1-Year Sharpe Ratio Related Terms

COO vs SOLV, ALGN, BAX: 1-Year Sharpe Ratio Comparison

For the Medical Instruments & Supplies subindustry, The Cooper's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Cooper 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where The Cooper's 1-Year Sharpe Ratio falls into.


COO
89GF Score
The Cooper Companies Inc COO
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Cooper 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.03 mean?
The Cooper (COO) has a 1-Year Sharpe Ratio of 0.03 as of Jul. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for The Cooper and its competitors.
Is The Cooper's 1-Year Sharpe Ratio too high?
The Cooper's current 1-Year Sharpe Ratio is 0.03. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's 1-Year Sharpe Ratio compare to SOLV and ALGN?
The Cooper's 1-Year Sharpe Ratio of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for The Cooper and its competitors. The Cooper's current 1-Year Sharpe Ratio is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.24, compared to a current price of $73.10 — trading 27.8% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.03. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For The Cooper (COO), the current 1-Year Sharpe Ratio is 0.03 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Cooper (COO) Overvalued in 2026?

Based on GuruFocus' analysis, The Cooper stock appears to be undervalued. The current stock price of $73.10 is trading 27.8% below its estimated GF Value™ of $101.24. GuruFocus considers The Cooper to be Modestly Undervalued.

Key valuation signals for COO:

  • 1-Year Sharpe Ratio: 0.03
  • GF Value™: $101.24 vs. price of $73.10 (27.8% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Cooper Business Description

Address 6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score

Get the complete analysis for COO

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$73.10
Price
$101.24
GF Value